• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ZF2001 亚单位疫苗和 RRV mRNA 疫苗固有免疫特征的转录组学分析

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV.

机构信息

Hepatitis virus and enterovirus vaccines Division, National Institutes for Food and Drug Control, Beijing, People's Republic of China.

NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, Beijing, People's Republic of China.

出版信息

Emerg Microbes Infect. 2022 Dec;11(1):1145-1153. doi: 10.1080/22221751.2022.2059404.

DOI:10.1080/22221751.2022.2059404
PMID:35343384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9037177/
Abstract

Analysis of large-scale gene expression post vaccination can provide an overview of immune responses. We used transcriptional approaches to comprehensively analyze the innate immune response signatures elicited by protein subunit (PS) vaccine ZF2001 and an mRNA vaccine named RRV. A fine-grained time-dependent dissection of large-scale gene expression post immunization revealed that ZF001 induced MHC class II-related genes, including and , more expeditiously than the RRV. Notably, the RRV induced MHC class I-related genes such as /, and /. At day 21 post immunization, the titres of binding and neutralization antibody (NAb) induced by both vaccines were comparable, which were accordant with the expression level of genes essential to BCR/TCR signalling transduction and B/T cells activation at day 7. However, compared to ZF2001, the early responses of RRV were more robust, including the activation of pattern recognition receptors (PRRs), expression of genes involved in RNA degradation, and transcription inhibition, which are directly related to anti-viral signals. This pattern also coincided with the induction of cytokines by the RRV. Generally, the transcriptomic patterns of two very different vaccines mapped here provide a framework for establishing correlates between the induction of genes and protection, which can be tailored for evoking specific and potent immune responses against SARS-CoV-2.

摘要

分析大规模基因表达后接种疫苗可以提供对免疫反应的概述。我们使用转录方法全面分析了由蛋白亚单位(PS)疫苗 ZF2001 和一种名为 RRV 的 mRNA 疫苗引起的固有免疫反应特征。对免疫后大规模基因表达的精细时间依赖性剖析表明,ZF001 比 RRV 更迅速地诱导 MHC Ⅱ类相关基因,包括 和 。值得注意的是,RRV 诱导 MHC Ⅰ类相关基因,如 / 、 和 / 。在免疫后第 21 天,两种疫苗诱导的结合抗体和中和抗体(NAb)的效价相当,这与 BCR/TCR 信号转导和 B/T 细胞激活所需基因的表达水平一致在第 7 天。然而,与 ZF2001 相比,RRV 的早期反应更为强烈,包括模式识别受体(PRRs)的激活、参与 RNA 降解的基因的表达以及转录抑制,这些都与抗病毒信号直接相关。这种模式也与 RRV 诱导细胞因子的情况相吻合。一般来说,这里映射的两种非常不同的疫苗的转录组模式为建立基因诱导与保护之间的相关性提供了一个框架,这可以针对引发针对 SARS-CoV-2 的特异性和有效的免疫反应进行定制。

相似文献

1
Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV.ZF2001 亚单位疫苗和 RRV mRNA 疫苗固有免疫特征的转录组学分析
Emerg Microbes Infect. 2022 Dec;11(1):1145-1153. doi: 10.1080/22221751.2022.2059404.
2
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
3
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.异源加强免疫用腺病毒 5 型载体和基于蛋白亚单位的 COVID-19 疫苗(Convidecia/ZF2001)的安全性和免疫原性:一项随机、观察者设盲、安慰剂对照试验。
PLoS Med. 2022 May 26;19(5):e1003953. doi: 10.1371/journal.pmed.1003953. eCollection 2022 May.
4
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.基于串联重复二聚体 RBD 蛋白的新冠疫苗 zf2001 可保护小鼠和非人灵长类动物。
Emerg Microbes Infect. 2022 Dec;11(1):1058-1071. doi: 10.1080/22221751.2022.2056524.
5
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
6
Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.SARS-CoV-2 mRNA 和重组蛋白候选疫苗引起的免疫反应比较。
Front Immunol. 2022 May 19;13:906457. doi: 10.3389/fimmu.2022.906457. eCollection 2022.
7
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
8
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性:一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
9
Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.细菌介导的基于复制子的 mRNA 疫苗候选物经口腔递送可预防原始和德尔塔变异 SARS-CoV-2。
Mol Ther. 2022 May 4;30(5):1926-1940. doi: 10.1016/j.ymthe.2022.01.042. Epub 2022 Feb 3.
10
Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.mRNA 疫苗接种后针对 SARS-CoV-2 变体 RBD 的中和抗体反应减弱和异质性。
Front Immunol. 2022 Apr 6;13:816389. doi: 10.3389/fimmu.2022.816389. eCollection 2022.

引用本文的文献

1
Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization.通过狂犬病病毒糖蛋白(RABV-G)结构域筛选和异源初免-加强免疫优化狂犬病信使核糖核酸(mRNA)疫苗效力
NPJ Vaccines. 2025 Mar 2;10(1):43. doi: 10.1038/s41541-025-01098-w.
2
A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.一种新型靶向 RIG-I 受体 5'三磷酸双链 RNA 佐剂显著提高了 SARS-CoV-2 德尔塔-奥密克戎嵌合 RBD-二聚体重组蛋白疫苗的免疫原性。
Viruses. 2023 Apr 29;15(5):1099. doi: 10.3390/v15051099.
3

本文引用的文献

1
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.mRNA-1273 新冠疫苗有效性临床试验的免疫相关性分析。
Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23.
2
Ubiquitination of ATF6 by disease-associated RNF186 promotes the innate receptor-induced unfolded protein response.疾病相关的RNF186对ATF6进行泛素化修饰可促进天然受体诱导的未折叠蛋白反应。
J Clin Invest. 2021 Sep 1;131(17). doi: 10.1172/JCI145472.
3
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model.
展示严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突受体结合结构域(RBD)的杆状病毒可促进小鼠模型中中和抗体的产生。
J Genet Eng Biotechnol. 2023 Feb 9;21(1):16. doi: 10.1186/s43141-023-00472-2.
4
Research progress on circular RNA vaccines.环状 RNA 疫苗的研究进展。
Front Immunol. 2023 Jan 12;13:1091797. doi: 10.3389/fimmu.2022.1091797. eCollection 2022.
5
Respiratory immune status and microbiome in recovered COVID-19 patients revealed by metatranscriptomic analyses.通过宏转录组分析揭示的 COVID-19 康复患者的呼吸免疫状态和微生物组。
Front Cell Infect Microbiol. 2022 Nov 22;12:1011672. doi: 10.3389/fcimb.2022.1011672. eCollection 2022.
6
Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses.基于mRNA和蛋白质的新冠疫苗混合制剂引发了更强的中和抗体反应。
MedComm (2020). 2022 Dec 2;3(4):e188. doi: 10.1002/mco2.188. eCollection 2022 Dec.
7
Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in human.人体第三剂加强针中 COVID-19 灭活疫苗和蛋白亚单位疫苗的体液免疫和转录组差异。
Front Immunol. 2022 Oct 21;13:1027180. doi: 10.3389/fimmu.2022.1027180. eCollection 2022.
8
A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.一种新型基于单链 RNA 的佐剂可提高 SARS-CoV-2 重组蛋白疫苗的免疫原性。
Viruses. 2022 Aug 24;14(9):1854. doi: 10.3390/v14091854.
9
Different T-cell and B-cell repertoire elicited by the SARS-CoV-2 inactivated vaccine and S1 subunit vaccine in rhesus macaques.恒河猴中由新冠灭活疫苗和 S1 亚单位疫苗引发的不同 T 细胞和 B 细胞反应。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2118477. doi: 10.1080/21645515.2022.2118477. Epub 2022 Sep 7.
针对有症状和无症状 SARS-CoV-2 感染的保护相关因素。
Nat Med. 2021 Nov;27(11):2032-2040. doi: 10.1038/s41591-021-01540-1. Epub 2021 Sep 29.
4
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients.与 BNT162b2 mRNA 疫苗接种者对 SARS-CoV-2 产生有效免疫反应相关的系统性 IL-15、IFN-γ 和 IP-10/CXCL10 特征。
Cell Rep. 2021 Aug 10;36(6):109504. doi: 10.1016/j.celrep.2021.109504. Epub 2021 Jul 23.
5
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.用异源疫苗加强免疫可有效提高灭活 SARS-CoV-2 疫苗的保护免疫应答。
Emerg Microbes Infect. 2021 Dec;10(1):1598-1608. doi: 10.1080/22221751.2021.1957401.
6
Systems vaccinology of the BNT162b2 mRNA vaccine in humans.人体中 BNT162b2 mRNA 疫苗的系统疫苗学。
Nature. 2021 Aug;596(7872):410-416. doi: 10.1038/s41586-021-03791-x. Epub 2021 Jul 12.
7
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.COVID-19 疫苗:免疫原性、安全性的现有认识及进一步的考虑因素。
Front Immunol. 2021 Apr 12;12:669339. doi: 10.3389/fimmu.2021.669339. eCollection 2021.
8
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗(ZF2001)在成年人中的安全性和免疫原性:两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
9
Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.使用类脂质材料递送信使核糖核酸疫苗通过Toll样受体4信号通路增强抗肿瘤疗效。
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2005191118.
10
mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.mRNA 疫苗时代——机制、药物平台和临床前景。
Int J Mol Sci. 2020 Sep 9;21(18):6582. doi: 10.3390/ijms21186582.